Bendamustine funding approved in New Zealand

15 June 2017

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with Janssen-Cilag Pty, a local unit of US healthcare giant Johnson & Johnson (NYSE: JNJ), for the listing of bendamustine.

This was the subject of a consultation letter dated 15 May 2017. The funding of bendamustine, marketed under the Ribomustin trade name, means that a new pharmaceutical used to treat chronic lymphocytic leukemia (CLL) and indolent Non-Hodgkin lymphoma (iNHL) will be funded, subject to restrictions, from 1 July 2017.

The proposal was broadly approved as consulted on except for small changes to Special Authority criteria, in that:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK